Molecular and Clinical Advances in Kidney Cancer

A special issue of Medical Sciences (ISSN 2076-3271). This special issue belongs to the section "Cancer and Cancer-Related Research".

Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 11823

Special Issue Editors


E-Mail Website
Guest Editor
Bureau for Cancer Research, New York, NY 10032, USA
Interests: renal cell carcinoma; drug development

E-Mail Website
Co-Guest Editor
Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Interests: renal cell carcinoma; cancer biology; drug development

Special Issue Information

Dear Colleagues,

Renal cell carcinoma accounts for approximately 4% of all malignant tumors with 431,288 new cases and 179,368 deaths annually worldwide (GLOBOCAN 2020). In most regions, an increase in the incidence of kidney cancer is observed, and this tumor could enter the top five most common solid tumors in men in 15 years.

Half of the patients have an advanced disease that requires systemic therapy. Currently, there is progress in the treatment of metastatic renal cell carcinoma associated with the discovery of novel targets and evaluation of the role of the immune response. Despite significant advances, less than 50% of patients with metastatic disease survive 5 years. Therefore, further research into the pathogenesis of kidney cancer is important.

This Special Issue aims to provide an update on the challenges of molecular and cellular advances in kidney cancer and highlight its expanding horizons. We invite authors to publish their original papers on basic and clinical research that evaluates new mechanisms, biomarkers, potential targets, the role of the microenvironment, and other important issues related to kidney cancer.

Dr. Ilya V. Tsimafeyeu
Dr. Petr Makhov
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medical Sciences is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • renal cell carcinoma
  • clear-cell RCC
  • papillary RCC
  • chromophobe RCC
  • rare types of kidney cancer
  • hereditary RCC
  • pathogenesis
  • pathology
  • biomarkers
  • new targets
  • immune system
  • targeted therapy
  • checkpoint inhibitors
  • vaccines

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Jump to: Other

25 pages, 8632 KiB  
Review
Hereditary Renal Cancer Syndromes
by Grigory A. Yanus, Ekaterina Sh. Kuligina and Evgeny N. Imyanitov
Med. Sci. 2024, 12(1), 12; https://doi.org/10.3390/medsci12010012 - 18 Feb 2024
Viewed by 2976
Abstract
Familial kidney tumors represent a rare variety of hereditary cancer syndromes, although systematic gene sequencing studies revealed that as many as 5% of renal cell carcinomas (RCCs) are associated with germline pathogenic variants (PVs). Most instances of RCC predisposition are attributed to the [...] Read more.
Familial kidney tumors represent a rare variety of hereditary cancer syndromes, although systematic gene sequencing studies revealed that as many as 5% of renal cell carcinomas (RCCs) are associated with germline pathogenic variants (PVs). Most instances of RCC predisposition are attributed to the loss-of-function mutations in tumor suppressor genes, which drive the malignant progression via somatic inactivation of the remaining allele. These syndromes almost always have extrarenal manifestations, for example, von Hippel–Lindau (VHL) disease, fumarate hydratase tumor predisposition syndrome (FHTPS), Birt–Hogg–Dubé (BHD) syndrome, tuberous sclerosis (TS), etc. In contrast to the above conditions, hereditary papillary renal cell carcinoma syndrome (HPRCC) is caused by activating mutations in the MET oncogene and affects only the kidneys. Recent years have been characterized by remarkable progress in the development of targeted therapies for hereditary RCCs. The HIF2aplha inhibitor belzutifan demonstrated high clinical efficacy towards VHL-associated RCCs. mTOR downregulation provides significant benefits to patients with tuberous sclerosis. MET inhibitors hold promise for the treatment of HPRCC. Systematic gene sequencing studies have the potential to identify novel RCC-predisposing genes, especially when applied to yet unstudied populations. Full article
(This article belongs to the Special Issue Molecular and Clinical Advances in Kidney Cancer)
Show Figures

Figure 1

Other

Jump to: Review

4 pages, 182 KiB  
Commentary
Sunitinib in Patients with Metastatic Renal Cell Carcinoma with Favorable Risk: Be Aware of PD-L1 Expression
by Ilya Tsimafeyeu
Med. Sci. 2024, 12(3), 48; https://doi.org/10.3390/medsci12030048 - 13 Sep 2024
Viewed by 8115
Abstract
The treatment landscape for metastatic renal cell carcinoma (RCC) has advanced significantly with first-line immunotargeted therapy combinations. However, no statistically significant differences were observed in the cohort of patients with favorable risk and some oncologists continue to use sunitinib in these patients. PD-L1 [...] Read more.
The treatment landscape for metastatic renal cell carcinoma (RCC) has advanced significantly with first-line immunotargeted therapy combinations. However, no statistically significant differences were observed in the cohort of patients with favorable risk and some oncologists continue to use sunitinib in these patients. PD-L1 expression has emerged as a negative prognostic factor in RCC, particularly in sunitinib-treated patients, where higher PD-L1 levels are linked to worse outcomes. This article discusses the potential risks associated with the use of sunitinib in PD-L1-positive patients. Full article
(This article belongs to the Special Issue Molecular and Clinical Advances in Kidney Cancer)
Back to TopTop